BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 2875864)

  • 1. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD; Grant SM; Goa KL
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Oct; 24(4):267-303. PubMed ID: 6128216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Price AH; Brogden RN
    Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H2 receptor antagonists.
    Siepler JK; Campagna KD; Donahue PE; Bombeck CT
    Am J Hosp Pharm; 1978 Feb; 35(2):141-5. PubMed ID: 24338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB; Mahachai V
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.
    Carmine AA; Brogden RN
    Drugs; 1985 Aug; 30(2):85-126. PubMed ID: 3928324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G
    Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.